# Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World

> **NCT03636984** · — · UNKNOWN · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 1000 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Ankylosing Spondylitis

## Interventions

- **DRUG:** recombinant TNF-α receptor: IgG Fc fusion protein

## Key facts

- **NCT ID:** NCT03636984
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-24
- **Primary completion:** 2020-07-24
- **Final completion:** 2020-12-24
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636984, "Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03636984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*